




A.




B.



C.



D.



Supplementary Figure 1: **a)** The average GI₅₀s for PTEN WT and mutant prostate cancer cells from Fig. 1a. **b)** Prostate cancer cell lines from Fig1a were treated with carboplatin; PTEN-deficient cells did not have a significantly lower GI₅₀ than PTEN WT cells. **c)** Prostate cancer cell lines from Fig1a were treated with paclitaxel; PTEN-deficient cells did not have a significantly lower GI₅₀ than PTEN WT cells. **d)** RWPE, 22RV1, PC3, and LNCAP cells were treated with 100μM leflunomide for 5 days and the number of dead cells (DRAQ7 positive cells) were recorded every 6 hours and normalized to the total number of cells. Experiments were done in triplicate (one-way ANOVA, *, P value on figure).